Anergis, of Eplinges, Switzerland, named Gilles Della Corte director of clinical development and Eva Castagnetti director of product development...Curis Inc., of Lexington, Mass., appointed Ali Fattaey president and chief operating officer...Mylan Inc., of Pittsburgh, added Melina Higgins and Rajiv Malik to its board

Probiodrug AG, of Halle, Germany, appointed Ronald Black chief medical officer and Inge Lues chief development officer...Rexahn Pharmaceuticals Inc., of Rockville, Md., named Peter D. Suzdak CEO and Chang AHN chief scientist...Spectrum Pharmaceuticals Inc., of Henderson, Nev., named Joseph Turgeon senior vice president and chief commercial officer

Cerecor Inc., of Baltimore, appointed James Vornov senior vice president, clinical development and regulatory affairs, and John Kaiser vice president of commercialization and business development

Imprimis Pharmaceuticals Inc., of Solana Beach, Calif., added Lee S. Simon and Allan Green to its science and regulatory advisory board...Islet Sciences Inc., of New York, added Kevan Herold and Morton Printz to its scientific advisory board

Actinium Pharmaceuticals Inc., of New York, hired Jack V. Talley as president and CEO and added Enza Guagenti as chief financial officer...BioMotiv LLC, of Cleveland, named Baiju R. Shah CEO and board member, effective Sept...ImmunoCellular Therapeutics Ltd., of Los Angeles, named John S. Yu interim CEO and president

Ruga Corp., of Palo Alto, Calif., appointed Patrick O'Connor vice president, head of oncology, R&D and James Freddo chief medical officer, head of clinical development...Vaximm AG, of Basel, Switzerland, and Mannheim, Germany, appointed Jean Paul Prieels to its board

named CFO Timothy Morris senior vice president, global corporate development and finance...and appointed Roman Dvorak senior director, clinical development

GlycoMimetics Inc., of Gaithersburg, Md., promoted Helen Thackray to chief medical officer and vice president of clinical development and named Brian Hahn chief financial officer

It also added John E. Dick and Janet Rossant to its scientific and clinical advisory board...Topica Pharmaceuticals Inc., of Palo Alto, Calif., added Amir Tavakkol as senior vice president of clinical development and operations

NeoStem Inc., of New York, appointed Martyn D. Greenacre and Andrew L. Pecora to the board...NexImmune Inc., of Gaithersburg, Md., appointed Kenneth Carter CEO and named Jonathan Schneck chairman of the clinical and scientific advisory board...Oncolytics Biotech Inc., of Calgary, Alberta, appointed Gerard Kennealey senior vice president of clinical development and chief medical officer

NeoStem Inc., of New York, appointed Martyn D. Greenacre and Andrew L. Pecora to the board...NexImmune Inc., of Gaithersburg, Md., appointed Kenneth Carter CEO and named Jonathan Schneck chairman of the clinical and scientific advisory board...Oncolytics Biotech Inc., of Calgary, Alberta, appointed Gerard Kennealey senior vice president of clinical development and chief medical officer

InteRNA Technologies BV, of Utrecht, the Netherlands, appointed Mark Vaeck and Sanne Weijzen to its board chaired by Anker Lundemose...It also named Robert B. Shapiro and Jeffrey B. Kindler to its board...Medivation Inc., of San Francisco, promoted Sarah Noonberg to vice president of clinical development

Dyax Corp., of Cambridge, Mass., appointed Ron Cohen and Paolo Pucci to its board...Scott L. Friedman and Maria Isabel Fiel were named as consultants...Horizon Pharma Inc., of Northbrook, Ill., appointed Michael Grey and Ronald Pauli to its board

PanOptica Inc., of Mount Arlington, N.J., added David P. Bingaman as senior director of clinical development and Kristine Curtiss as executive director of clinical operations...PolyTherics Ltd., of London, named John Burt CEO and board member after Keith Powell stepped down...Resolve Therapeutics LLC, of Seattle, named Peter Kiener chairman and added Somu Subramaniam as an observer to the board

Addex Pharmaceuticals Ltd., of Geneva, added Hoyoung Huh and Oleg Nodelman to its board...Agennix AG, of Planegg, Germany, appointed Steven Simonson vice president of clinical development...Aileron Therapeutics Inc., of Cambridge, Mass., named Julian Adams, Scott Kapnick and John H. McArthur to its board, and named Stephen W. Fesik, Robert H. Grubbs and Michael Hanley to its scientific advisory board

Allon Therapeutics Inc., of Vancouver, British Columbia, appointed Michael Gold vice president of clinical development and chief medical officer...It also added Michael Handelman as chief financial officer, treasurer and secretary...Medgenics Inc., of Misgav, Israel, added Isaac Blech and Raymond Dean Hautamaki to its board

Lund most recently was former global vice president of clinical development activities at London-based AstraZeneca plc...He previously served as executive vice president of Abbott Corp., of Abbott Park, Ill., and president of its pharmaceutics division, in addtion to group president for Europe and subsequently president of Abbott International

Celsion Corp., of Columbia, Md., appointed Sid Taubenfeld director of communications and strategic initiatives and named Robert W. Hooper to its board...PharmaGap Inc., of Ottawa, Ontario, appointed Ken Sokoll vice president of clinical development and chief operating officer

Ablexis LLC, of San Francisco, appointed Scott Greer chairman and named Richard Hoffman chief business officer...Bioheart Inc., of Sunrise, Fla., appointed Mike Tomas president, CEO and board member, replacing Karl Groth, who will retain his position as chairman...CalciMedica, of La Jolla, Calif., appointed Steven L. Schoenfeld vice president of clinical development